Key Drivers
- Margin Expansion
- Strong Liquidity
- High Leverage
AIAI Summary
HAE is evolving into a higher-quality recurring-revenue medtech platform through CSL-backed plasma consumables and MedSurg expansion, but at ~40x earnings investors should only add on evidence of sustained plasma stability, margin expansion, and vascular-closure adoption, as any execution miss could trigger sharp valuation compression.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Expansion
- •Strong Liquidity
- •High Leverage
HAE shows improving margins, strong cash flow and liquidity, but elevated valuation, high debt, and intangible-asset exposure warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Strong rebound
- •Key resistance
- •Pullback risk
HAE rebounded strongly over the last month but must break and hold above $108.80 to sustain momentum, while a drop below $106.20 could trigger a pullback toward $102–$103.
Sharp 7% rebound from the $101.06 low highlights elevated volatility
Sentiment & News
Key News Insights:
- •Recurring Revenue
- •CSL Agreement
- •MedSurg Growth
Haemonetics' recurring plasma revenue, higher-margin MedSurg growth, and CSL agreement support a constructive outlook despite unclear valuation-comparison signals.
The news is modestly positive for HAE, reinforcing its growth profile and margin potential
Similar Companies in Healthcare
Other companies in the same sector with AI ratings